Unipolar Depression – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

MARKET OUTLOOK

The major depressive disorder (MDD) therapy market is mature, with numerous safe and effective treatment options available as inexpensive generics, which presents a challenge for branded agents attempting to gain traction in the United States. Nevertheless, the MDD population’s heterogenous response to treatment—and the need for additional efficacious therapies—gives new branded agents the opportunity to be incorporated into the treatment algorithm. This claims data analysis provides insights into how both long-established and newer-to-market agents fit into this crowded and competitive drug market.

QUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed MDD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed MDD patients?
  • How have Trintellix (Takeda / Lundbeck’s vortioxetine), Rexulti (Otsuka / Lundbeck’s brexpiprazole), and Spravato (Janssen’s esketamine) been integrated into the treatment algorithm, and what is their source of business?
  • What percentage of MDD patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of MDD patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Markets covered: United States

Key companies: AbbVie, Janssen, Lundbeck, Otsuka Pharmaceutical, Sunovion, Takeda Pharmaceutical

Key drugs: aripiprazole, bupropion, duloxetine, Latuda, Rexulti, sertraline, Spravato, Trintellix, Viibryd, Vraylar

Table of contents

  • Unipolar Depression - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
    • Treatment Algorithms CDA Major Depressive Disorder US March 2021
    • Treatment Algorithms CDA Major Depressive Disorder US 2021 Dashboard

launch Related Market Assessment Reports